Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | HPGD | P15428 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22149726 | 1.00 | MAPT (0.41) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149518 | 0.83 | MAPT (0.44) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149509 | 0.83 | MAPT (0.44) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149256 | 0.83 | MAPT (0.44) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149724 | 0.77 | L3MBTL1 (0.44) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149727 | 0.77 | CYP3A4 (0.38) | MAPTTDP1MEN1POLBAPEX1 | |
| SCHEMBL22149254 | 0.77 | L3MBTL1 (0.44) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL26046527 | 0.70 | ALDH1A1 (0.46) | MAPTL3MBTL1TDP1MEN1POLB | |
| SCHEMBL22149725 | 0.70 | KDM4E (0.42) | MAPTTDP1POLBALDH1A1HPGD | |
| SCHEMBL22149505 | 0.70 | KDM4E (0.42) | MAPTTDP1POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | MAPT 3137/4885L3MBTL1 1432/4885TDP1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.